Online citations, reference lists, and bibliographies.

Management Of Noninvasive Bladder Cancers

John B. Eifler, Kristen R. Scarpato, Peter E. Clark
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose of review To summarize clinical management of nonmuscle-invasive bladder cancer (NMIBC) and discuss recent advances in the field. Recent findings NMIBC remains a common and expensive clinical entity. Prevention, early detection, and risk-adapted treatment are the mainstays of clinical management, all of which may improve as a result of recent research. Photodynamic diagnosis has demonstrated improved detection of nascent disease, and specific clinical scenarios have been identified in which photodynamic diagnosis may improve clinical outcomes. New intravesical chemotherapeutic and immunotherapeutic agents challenge our current paradigm for intermediate/high-risk NMIBC and may delay need for cystectomy after bacillus Calmette–Guerin failure. Progress in risk stratification increasingly permits individualized management regimens for NMIBC. Summary NMIBC includes many heterogeneous disease states with a variety of clinical behaviors that may evolve over time. Improved detection and risk stratification promise assignment of the optimal treatment option for an individual patient at a given time.
This paper references
Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high - risk of recurrence and progression who have failed treatment with bacillus CalmetteGuerin
A Morales (2014)
10.1002/ijc.28830
Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer.
Paola Gazzaniga (2014)
10.1111/bju.12448
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
Malte Rieken (2013)
10.1016/j.juro.2013.07.102
Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition.
Donald L. Lamm (2014)
10.1016/j.eururo.2009.05.047
Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.
Paramananthan Mariappan (2010)
The effect of smoking and timing of smoking cessation on clinical outcome in nonmuscleinvasive bladder cancer
AJ Grotenhuis (2014)
10.1038/bjc.2013.372
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
Evangelos Xylinas (2013)
10.1158/1078-0432.CCR-04-0378
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
W. Jeffrey Allard (2004)
10.1002/cncr.29071
Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link.
Karim Chamie (2015)
Circulating tumor cells detection has independent prognostic impact in high - risk nonmuscle invasive bladder cancer
P Gazzaniga (2014)
P < 0.001) was improved with HAL-BLC. There was a significant reduction in recurrence overall (34.5% vs. 45.4%, RR 0.761, P ¼ 0.006)
Ta Detection Of
10.1016/j.urolonc.2012.04.010
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Colin P. N. Dinney (2013)
10.1111/j.1464-410X.2011.10880.x
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Michael D Shelley (2012)
10.1016/j.juro.2013.04.031
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Eila Curlee Skinner (2013)
10.1016/j.urology.2013.04.007
Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
Tianyuan Xu (2013)
10.1007/s00592-014-0562-6
Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes
Chin-Hsiao Tseng (2014)
10.1002/cncr.28905
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
10.1111/bju.12877
The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity?
M. Francesca Monn (2015)
10.1016/j.eururo.2011.04.023
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.
Rianne J. M. Lammers (2011)
10.1038/nrurol.2014.245
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
Siamak Daneshmand (2014)
10.1097/00001622-199206000-00003
Bladder cancer.
H A Ozen (1998)
10.1016/J.JURO.2007.09.003
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
Matthew C. Hall (2007)
10.1016/j.eururo.2005.12.031
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Richard J. Sylvester (2006)
10.1016/j.eururo.2013.03.059
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Maximilian Burger (2013)
10.1111/bju.12150
Effect of statin use on outcomes of non-muscle-invasive bladder cancer.
Joseph J. Crivelli (2013)
Detection and clinical outcome of urinary bladder cancer with 5aminolevulinic acidinduced fluorescence cystoscopy : a multicenter randomized , double - blind , placebo - controlled trial
A Stenzl (2011)
10.1002/cncr.25523
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.
Arnulf Stenzl (2011)
10.1016/J.EURURO.2007.10.006
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Jesús M Fernández-Gómez (2008)
10.1111/j.1464-410X.2010.09635.x
Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens.
Matthew J. Resnick (2011)
10.1007/s00345-014-1383-5
Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome
Tina Schubert (2014)
10.1016/j.urolonc.2014.05.009
Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.
Steffen Rausch (2014)
10.1016/j.urology.2012.09.040
Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.
Vincenzo Serretta (2013)
10.1016/j.clgc.2012.10.002
Prognostic value of the lymphovascular invasion in high-grade stage pT1 bladder cancer.
Julien Branchereau (2013)
10.1097/00005392-199907000-00018
The value of a second transurethral resection in evaluating patients with bladder tumors.
Harry W. Herr (1999)
10.1016/j.juro.2013.04.120
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Itay A Sternberg (2013)
10.1016/j.urolonc.2014.10.001
Contemporary bladder cancer: variant histology may be a significant driver of disease.
M. Francesca Monn (2015)
10.1016/j.juro.2013.01.089
Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
Luis A. Kluth (2013)
10.1016/j.eururo.2012.10.039
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
Jorg R. Oddens (2013)
10.1016/j.eururo.2012.08.025
Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer.
Michael Rink (2013)
Association of diabetes mellitus and metformin use with oncological outcomes of patients with nonmuscleinvasive bladder cancer
M Rieken (2013)
10.1016/j.juro.2012.10.054
The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy.
Ahmed Abd El-Latif (2013)
10.1016/j.juro.2014.02.2573
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.
Ashish M. Kamat (2014)
EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update
M Babjuk (2013)
Hexyl aminolevulinateguided fluorescence cystoscopy in the diagnosis and follow - up of patients with nonmuscleinvasive bladder cancer : a critical review of the current literature
M Rink (2013)
10.1002/cncr.28915
Knowledge of the harms of tobacco use among patients with bladder cancer.
Jeffrey C. Bassett (2014)
10.1016/j.urology.2014.03.006
Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.
Johannes Alfred Witjes (2014)
10.3322/canjclin.39.6.399
Cancer statistics.
N Dubrawsky (1989)
10.1016/J.EURURO.2009.05.047
Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience
Guido Dalbagni (2010)
10.3322/caac.21208
Cancer statistics, 2014.
Rebecca L Siegel (2014)
10.1016/j.eururo.2013.06.003
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Marko Babjuk (2013)
10.1016/j.eururo.2013.07.007
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Michael Rink (2013)
10.1007/s00432-014-1795-z
Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer
Mitsuo Ofude (2014)
SWOG S 0353 : phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus CalmetteGuerin
EC Skinner (2013)
10.6004/JNCCN.2013.0059
Bladder cancer. Clinical practice guidelines in oncology.
James E. Montie (2005)
10.2337/dc13-1489
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
Ronac Mamtani (2014)
Neutrophil - tolymphocyte ratio predicts progression and recurrence of nonmuscleinvasive bladder cancer
R Mano (2014)
10.1016/j.urology.2003.11.049
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
A. Boehle (2004)
10.1016/j.eururo.2014.06.037
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
J. Alfred Witjes (2014)



This paper is referenced by
10.1016/j.urolonc.2015.05.010
Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4).
Alvaro Morales (2015)
10.3233/BLC-189037
A Festschrift in Honor of Edward M. Messing, MD, FACS
Jean V. Joseph (2018)
10.1186/s13046-016-0408-x
Interplay between intergrin-linked kinase and ribonuclease inhibitor affects growth and metastasis of bladder cancer through signaling ILK pathways
Xiang Zhuang (2016)
10.3390/cells8060526
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment
Ekaterina A. Blinova (2019)
10.1007/s10637-019-00861-w
7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells
Mariana Souza Sonego (2019)
10.3892/ol.2017.6080
Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer
Zhi-hua Liu (2017)
10.1371/journal.pone.0188093
Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model
Noboru Sasaki (2017)
10.3390/cancers12051316
Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy
Ekaterina A. Blinova (2020)
10.1177/1010428317691183
The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer
Hongshuo Zhang (2017)
Semantic Scholar Logo Some data provided by SemanticScholar